title: Simvastatin ameliorates glomerulosclerosis in Adriamycin-induced-nephropathy rats.
abstract: The aim of this study was to investigate the effects of simvastatin, a competitive inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, on inflammation and glomerulosclerosis in Adriamycin (ADR)-induced nephropathy. Male Sprague-Dawley rats were randomly divided into control, ADR nephrosis, and simvastatin-treated ADR nephrosis groups. ADR nephropathy was induced by a single-tail intravenous injection of ADR (6.5 mg/kg). Anti-inflammatory effects of simvastatin were studied by evaluating the expression of the inflammatory mediators interleukin-1 beta (IL-1beta), transforming growth factor-beta1 (TGF-beta1), and transcription factor nuclear factor kappa B (NF-kappaB). In addition, renal function, serum lipid levels, and histopathology were compared between groups. Simvastatin significantly decreases IL-1beta and TGF-beta1 expression and NF-kappaB activation, accompanied by significant attenuation of glomerulosclerosis and renal function at 12 weeks after ADR injection, and these changes occurred in the absence of lowering of serum lipids. These results suggest that overexpression of inflammation in the renal region may contribute to development of glomerulosclerosis in ADR-induced-nephropathy rats, and simvastatin treatment prevented glomerulosclerosis independent of the lipid-lowering effects. The beneficial effect of simvastatin might be mediated by the effect of anti-inflammatory action through a reduction of NF-kappaB activation, and IL-1beta and TGF-beta expression.
authors.affiliation: Department of Nephroimmunology, Children's Hospital of Chongqing Medical University, Chongqing, People's Republic of China.
authors.forename: Wei
authors.initials: W
authors.lastname: Zhang
authors.forename: Qiu
authors.initials: Q
authors.lastname: Li
authors.forename: Lijia
authors.initials: L
authors.lastname: Wang
authors.forename: Xiqiang
authors.initials: X
authors.lastname: Yang
mesh_terms: D000818:Animals; D000903:Antibiotics, Antineoplastic / Q000009:adverse effects*; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000009:adverse effects*; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D053583:Interleukin-1beta / Q000378:metabolism; D007668:Kidney / Q000187:drug effects / Q000378:metabolism / Q000473:pathology*; D007674:Kidney Diseases / Q000139:chemically induced* / Q000473:pathology / Q000517:prevention & control*; D008297:Male; D016328:NF-kappa B / Q000378:metabolism; D051381:Rats; D017207:Rats, Sprague-Dawley; D012598:Sclerosis; D019821:Simvastatin / Q000494:pharmacology / Q000627:therapeutic use*; D053773:Transforming Growth Factor beta1 / Q000378:metabolism
chemical_list: D000903:Antibiotics, Antineoplastic; D019161:Hydroxymethylglutaryl-CoA Reductase Inhibitors; D053583:Interleukin-1beta; D016328:NF-kappa B; D053773:Transforming Growth Factor beta1; D004317:Doxorubicin; D019821:Simvastatin
references.citation: J Am Soc Nephrol. 2004 Apr;15(4):910-8
references.pmid: 15034093
references.citation: Nephrol Dial Transplant. 1997 Jun;12(6):1109-15
references.pmid: 9198037
references.citation: Kidney Int. 2002 May;61(5):1635-45
references.pmid: 11967013
references.citation: EMBO J. 1990 May;9(5):1503-10
references.pmid: 2328723
references.citation: Kidney Int. 2005 Sep;68(3):1041-7
references.pmid: 16105034
references.citation: J Am Soc Nephrol. 2005 Jul;16(7):1936-47
references.pmid: 15843472
references.citation: Nephrol Dial Transplant. 2002 May;17(5):798-802
references.pmid: 11981066
references.citation: Am J Physiol Heart Circ Physiol. 2000 Dec;279(6):H2786-96
references.pmid: 11087233
references.citation: Circulation. 1995 Nov 1;92(9):2419-25
references.pmid: 7586340
references.citation: Kidney Int. 2001 Feb;59(2):415-24
references.pmid: 11168923
references.citation: Kidney Int. 1997 Aug;52(2):393-403
references.pmid: 9263995
references.citation: Kidney Int. 1995 Dec;48(6):1738-46
references.pmid: 8587234
references.citation: Am J Physiol Renal Physiol. 2004 Jan;286(1):F46-57
references.pmid: 14519596
references.citation: Nephrol Dial Transplant. 2003 Feb;18(2):265-72
references.pmid: 12543879
references.citation: Nature. 1990 Feb 1;343(6257):425-30
references.pmid: 1967820
references.citation: Kidney Int. 2003 Aug;64(2):565-71
references.pmid: 12846751
references.citation: Lancet. 1974 Sep 7;2(7880):556-60
references.pmid: 4140273
references.citation: N Engl J Med. 1995 Nov 16;333(20):1301-7
references.pmid: 7566020
references.citation: Am J Kidney Dis. 1990 Jan;15(1):16-23
references.pmid: 2294729
references.citation: Am J Nephrol. 2006;26(6):562-70
references.pmid: 17167242
references.citation: Blood. 2004 Jun 1;103(11):4188-94
references.pmid: 14976045
references.citation: J Am Soc Nephrol. 2000 Jan;11(1):152-176
references.pmid: 10616852
references.citation: N Engl J Med. 1997 Apr 10;336(15):1066-71
references.pmid: 9091804
references.citation: J Biol Chem. 2001 Sep 21;276(38):35382-9
references.pmid: 11457826
references.citation: J Am Soc Nephrol. 2006 Mar;17(3):754-64
references.pmid: 16452496
references.citation: Pharmacol Rep. 2007 Sep-Oct;59(5):483-99
references.pmid: 18048949
references.citation: Clin Exp Immunol. 1992 Nov;90(2):312-8
references.pmid: 1385027
references.citation: Nephron. 1998;78(4):440-52
references.pmid: 9578071